Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC.ACTU · Entity 7370 | Director | May 21, 2026 | May 22, 2026 |
| ALIMERA SCIENCES INCALIM · Entity 11664 | Director | February 25, 2023 | March 01, 2023 |
| Adlai Nortye Group Ltd.ANL · Entity 5049 | Director | March 18, 2026 | July 15, 2026 |
| Arbutus Biopharma CorpABUS · Entity 4953 | Director | October 01, 2026 | October 07, 2026 |
| Omega Therapeutics, Inc.OMGA · Entity 83618 | Chief Financial Officer | March 09, 2022 | March 11, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACTUATE THERAPEUTICS, INC.
Report date May 21, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.42 · Expires 2036-05-21 | Direct | 15,000 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 15,000 · Balance 15,000 F1: Options will vest in full on the anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Options will vest in full on the anniversary of the grant date.
ALIMERA SCIENCES INC
Report date February 25, 2023 · Filed March 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.21 · Expires 2033-02-24 | Direct | 2,252 |
Reported balance
After 2023-02-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-25 · Grant · Acquired 2,252 · Balance 2,252 F1: The closing price for the Issuer's common stock on the Nasdaq Global Market on February 27, 2023, the first trading day after the grant of the options. F2: Options vest monthly and become exercisable in equal monthly installments beginning on March 12, 2023, and ending on July 12, 2023, with the final installment adjusted as necessary to avoid any fractional shares in any installment. |
Filing footnotes · ownership attribution and instrument terms
F1: The closing price for the Issuer's common stock on the Nasdaq Global Market on February 27, 2023, the first trading day after the grant of the options.
F2: Options vest monthly and become exercisable in equal monthly installments beginning on March 12, 2023, and ending on July 12, 2023, with the final installment adjusted as necessary to avoid any fractional shares in any installment.
Adlai Nortye Group Ltd.
Report date March 18, 2026 · Filed July 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 9,838 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 9,838 |
| Restricted Share UnitsSEC Table II · derivative / convertible security | IndirectHeld by ESOP(Nortye International Limited) | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: Each RSU represents a right to receive one (1)share of ADS upon settlement. F1: Do not have an expiration date. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | IndirectHeld by ESOP(Nortye International Limited) | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F2: Each RSU represents a right to receive one (1)share of ADS upon settlement. F3: Vests quarterly: 834 ADSs on 8/8/2026, 11/8/2026, 2/8/2027, and 5/8/2027; remaining 826 ADSs on 8/8/2027. F1: Do not have an expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Do not have an expiration date.
F2: Each RSU represents a right to receive one (1)share of ADS upon settlement.
F3: Vests quarterly: 834 ADSs on 8/8/2026, 11/8/2026, 2/8/2027, and 5/8/2027; remaining 826 ADSs on 8/8/2027.
Arbutus Biopharma Corp
Report date October 01, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 13,683 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Disposition to issuer · Disposed 17,142 · Balance 13,683 F1: Represents common shares tendered to the Issuer pursuant to the Issuer's tender offer. The Issuer took up and accepted the common shares for payment on October 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents common shares tendered to the Issuer pursuant to the Issuer's tender offer. The Issuer took up and accepted the common shares for payment on October 1, 2026.
Omega Therapeutics, Inc.
Report date March 09, 2022 · Filed March 11, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.34 · Expires 2032-03-08 | Direct | 60,000 |
Reported balance
After 2022-03-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-09 · Grant · Acquired 60,000 · Balance 60,000 F1: The options vest and become exercisable with respect to 25% of the underlying shares on March 9, 2023 and in equal quarterly installments thereafter such that the option will become fully vested and exercisable on March 9, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable with respect to 25% of the underlying shares on March 9, 2023 and in equal quarterly installments thereafter such that the option will become fully vested and exercisable on March 9, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 7, 2026 20:09 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | Disposition to issuerCommon Shares | 17,142 | $5.00 | $85,710.00 |
DisclosureSEC source: 0001447028-26-000059 · wk-form4_1791403791.xml · nonDerivative · entry 1 Sawhney Roger · CIK 0001858748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,683 F1 · shares: Represents common shares tendered to the Issuer pursuant to the Issuer's tender offer. The Issuer took up and accepted the common shares for payment on October 1, 2026. Read SEC document |
| September 18, 2026 Filed Sep 24, 2026 00:31 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | Exercise / conversionStock Option (Right to Buy) · Derivative | 78,800 | $0.00 Strike: $4.24 | $0.00 |
DisclosureSEC source: 0001447028-26-000051 · wk-form4_1790209875.xml · derivative · entry 5 Sawhney Roger · CIK 0001858748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 78,800 shares Expires 2036-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing a right to purchase a total of 78,800 shares, was fully vested and exercisable as of the June 8, 2026 grant date. Read SEC document |
| September 18, 2026 Filed Sep 24, 2026 00:31 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | Exercise / conversionStock Option (Right to Buy) · Derivative | 52,533 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0001447028-26-000051 · wk-form4_1790209875.xml · derivative · entry 4 Sawhney Roger · CIK 0001858748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,067 Underlying: Common Shares · 52,533 shares Expires 2035-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, representing a right to purchase a total of 157,600 shares, vests over a three-year period, with 1/3rd of the total shares subject to the option vesting at each of the 1st, 2nd and 3rd anniversaries of the August 4, 2025 grant date, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| September 18, 2026 Filed Sep 24, 2026 00:31 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | Tax withholdingCommon Shares | 100,508 | $5.07 | $509,575.56 |
DisclosureSEC source: 0001447028-26-000051 · wk-form4_1790209875.xml · nonDerivative · entry 3 Sawhney Roger · CIK 0001858748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,825 F1 · kind: The Reporting Person exercised options on September 18, 2026. The Issuer withheld an aggregate of 100,508 shares otherwise issuable upon the exercises to satisfy the aggregate exercise prices. Read SEC document |
| September 18, 2026 Filed Sep 24, 2026 00:31 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | Exercise / conversionCommon Shares | 78,800 | $4.24 | $334,112.00 |
DisclosureSEC source: 0001447028-26-000051 · wk-form4_1790209875.xml · nonDerivative · entry 2 Sawhney Roger · CIK 0001858748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 18, 2026 Filed Sep 24, 2026 00:31 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | Exercise / conversionCommon Shares | 52,533 | $3.34 | $175,460.22 |
DisclosureSEC source: 0001447028-26-000051 · wk-form4_1790209875.xml · nonDerivative · entry 1 Sawhney Roger · CIK 0001858748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 20:05 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 78,800 | $0.00 Strike: $4.24 | $0.00 |
DisclosureSEC source: 0001447028-26-000040 · wk-form4_1781121928.xml · derivative · entry 1 Sawhney Roger · CIK 0001858748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,800 Underlying: Common Shares · 78,800 shares Expires 2036-06-08 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F2 · derivative.exercise_date: The option is fully vested and exercisable as of the date of the grant. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:10 UTC | ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370 | GrantStock Options · Derivative | 15,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001683168-26-004255 · ownership.xml · derivative · entry 1 Sawhney Roger · CIK 0001858748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-05-21 F1 · derivative.exercise_date: Options will vest in full on the anniversary of the grant date. Read SEC document |
| August 04, 2025 Filed Aug 6, 2025 20:08 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 157,600 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0001447028-25-000120 · wk-form4_1754510902.xml · derivative · entry 1 Sawhney Roger · CIK 0001858748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,600 Underlying: Common Shares · 157,600 shares Expires 2035-08-04 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F2 · derivative.exercise_date: This option vests over a three-year period, with 1/3rd of the total shares subject to the option vesting at each of the 1st, 2nd, and 3rd anniversaries of the grant date, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| May 22, 2025 Filed May 23, 2025 20:05 UTC | ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370 | GrantStock Options · Derivative | 15,000 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001683168-25-003993 · ownership.xml · derivative · entry 1 Sawhney Roger · CIK 0001858748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-05-22 F1 · derivative.exercise_date: Options will vest in full on the anniversary of the grant date. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 23:25 UTC | ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370 | GrantNon-Qualified Stock Options · Derivative | 30,000 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001104659-24-089791 · tm2421559-6_4seq1.xml · derivative · entry 1 Sawhney Roger · CIK 0001858748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-08-12 F1 · derivative.exercise_date: 30,000 stock options granted upon the effectiveness of the registration statement for the issuer's initial public offering on August 12, 2024, which vest in three equal installments on the first, second, and third anniversary of the grant date, subject to the reporting person's continued service through each such vesting date. Read SEC document |
| February 25, 2023 Filed Mar 1, 2023 16:25 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantStock Option (Right to Buy) · Derivative | 2,252 | $0.00 Strike: $2.21 | $0.00 |
DisclosureSEC source: 0001474506-23-000074 · primary_doc.xml · derivative · entry 1 Sawhney Roger · CIK 0001858748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,252 Underlying: Common Stock · 2,252 shares Expires 2033-02-24 F1 · derivative.exercise_price: The closing price for the Issuer's common stock on the Nasdaq Global Market on February 27, 2023, the first trading day after the grant of the options. F2 · derivative.exercise_date: Options vest monthly and become exercisable in equal monthly installments beginning on March 12, 2023, and ending on July 12, 2023, with the final installment adjusted as necessary to avoid any fractional shares in any installment. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 21:05 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantOption (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0000899243-22-010691 · doc4.xml · derivative · entry 1 Sawhney Roger · CIK 0001858748 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-03-08 F1 · derivative.exercise_date: The options vest and become exercisable with respect to 25% of the underlying shares on March 9, 2023 and in equal quarterly installments thereafter such that the option will become fully vested and exercisable on March 9, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| August 03, 2021 Filed Aug 3, 2021 21:16 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | PurchaseCommon Stock | 2,941 | $17.00 | $49,997.00 |
DisclosureSEC source: 0000899243-21-031305 · doc4.xml · nonDerivative · entry 1 Sawhney Roger · CIK 0001858748 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,941 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.